AU2017312361B2 - T cell receptors and immune therapy using the same - Google Patents

T cell receptors and immune therapy using the same Download PDF

Info

Publication number
AU2017312361B2
AU2017312361B2 AU2017312361A AU2017312361A AU2017312361B2 AU 2017312361 B2 AU2017312361 B2 AU 2017312361B2 AU 2017312361 A AU2017312361 A AU 2017312361A AU 2017312361 A AU2017312361 A AU 2017312361A AU 2017312361 B2 AU2017312361 B2 AU 2017312361B2
Authority
AU
Australia
Prior art keywords
ser
leu
seq
tcr
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017312361A
Other languages
English (en)
Other versions
AU2017312361A1 (en
Inventor
Leonie ALTEN
Sebastian Bunk
Dominik Maurer
Steffen Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60419980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017312361(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Publication of AU2017312361A1 publication Critical patent/AU2017312361A1/en
Application granted granted Critical
Publication of AU2017312361B2 publication Critical patent/AU2017312361B2/en
Priority to AU2021201518A priority Critical patent/AU2021201518A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2017312361A 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same Ceased AU2017312361B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021201518A AU2021201518A1 (en) 2016-08-17 2021-03-10 T cell receptors and immune therapy using the same

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662376059P 2016-08-17 2016-08-17
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie
US62/376,059 2016-08-17
DE102016115246.3 2016-08-17
US201662376632P 2016-08-18 2016-08-18
US62/376,632 2016-08-18
PCT/EP2017/066630 WO2018033291A1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021201518A Division AU2021201518A1 (en) 2016-08-17 2021-03-10 T cell receptors and immune therapy using the same

Publications (2)

Publication Number Publication Date
AU2017312361A1 AU2017312361A1 (en) 2019-02-28
AU2017312361B2 true AU2017312361B2 (en) 2020-12-10

Family

ID=60419980

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017312361A Ceased AU2017312361B2 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same
AU2021201518A Abandoned AU2021201518A1 (en) 2016-08-17 2021-03-10 T cell receptors and immune therapy using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021201518A Abandoned AU2021201518A1 (en) 2016-08-17 2021-03-10 T cell receptors and immune therapy using the same

Country Status (18)

Country Link
US (2) US10550182B2 (enExample)
EP (1) EP3500593B1 (enExample)
JP (2) JP6964351B2 (enExample)
CN (1) CN109563149A (enExample)
AU (2) AU2017312361B2 (enExample)
BR (1) BR112019001922A2 (enExample)
CA (1) CA3031995A1 (enExample)
CR (1) CR20190095A (enExample)
DE (1) DE102016115246C5 (enExample)
DK (1) DK3500593T3 (enExample)
LT (1) LT3500593T (enExample)
MA (1) MA45976B1 (enExample)
MX (1) MX395287B (enExample)
PE (1) PE20190477A1 (enExample)
RS (1) RS62498B1 (enExample)
SG (1) SG11201900955VA (enExample)
TW (1) TWI775768B (enExample)
WO (1) WO2018033291A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
ZA201900664B (en) * 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
EP3595708A4 (en) * 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES
CN111655280B (zh) 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
KR20250052472A (ko) 2017-11-06 2025-04-18 이매틱스 바이오테크놀로지스 게엠베하 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법
JP7470640B2 (ja) 2018-02-09 2024-04-18 イマティクス ユーエス，アイエヌシー． Ｔ細胞を製造する方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US12195769B2 (en) 2018-06-19 2025-01-14 Dsm Ip Assets B.V. Lipolytic enzyme variants
AU2020211922B2 (en) * 2019-01-22 2025-05-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted T cell receptors against RAS with G12R mutation
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
MA56036A (fr) 2019-05-27 2022-04-06 Immatics Us Inc Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CA3171370A1 (en) * 2020-03-16 2021-09-23 Ugur Sahin Antigen-specific t cell receptors and t cell epitopes
CN116096740A (zh) * 2020-06-09 2023-05-09 得克萨斯州大学系统董事会 经改造t细胞受体和使用方法
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
PE20250846A1 (es) 2020-12-31 2025-03-21 Immatics Us Inc Polipeptidos cd8, composiciones y metodos de uso de estos
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス，アイエヌシー． 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
EP4408468A4 (en) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc MULTIPLE FORMATS OF MOLECULAR COMPLEXES
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026046995A1 (en) * 2024-08-28 2026-03-05 Pairx Bio Pte. Ltd T cell receptors and uses thereof
CN120718134B (zh) * 2025-08-25 2025-12-26 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113819A2 (en) * 2010-03-19 2011-09-22 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2006023382A2 (en) * 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagen vi and cancer
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
AU2015289644A1 (en) * 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
HRP20201351T1 (hr) * 2014-11-05 2020-11-27 Genentech, Inc. Postupci proizvodnje dvolančanih proteina u bakteriji

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113819A2 (en) * 2010-03-19 2011-09-22 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMBL ACCESSION No. BAS03375 30 July 2015"Homo sapiens (human) partial T cell receptor alpha chain V-J-region",(Unpublished)Sequence is 93.33% identical to SEQ ID NO:15. *
EMBL ACCESSION No. BAS04242 30 July 2015"Homo sapiens (human) partial T cell receptor beta chain V-D-J-region",(Unpublished)Sequence is 92.31 % identical to SEQ ID NO:9 *

Also Published As

Publication number Publication date
RS62498B1 (sr) 2021-11-30
TW201806973A (zh) 2018-03-01
SG11201900955VA (en) 2019-03-28
MA45976A (fr) 2021-05-19
TWI775768B (zh) 2022-09-01
BR112019001922A2 (pt) 2019-07-09
US10550182B2 (en) 2020-02-04
US20180319884A1 (en) 2018-11-08
EP3500593A1 (en) 2019-06-26
LT3500593T (lt) 2021-11-25
US20180051080A1 (en) 2018-02-22
AU2017312361A1 (en) 2019-02-28
AU2021201518A1 (en) 2021-04-01
CN109563149A (zh) 2019-04-02
DE102016115246B3 (de) 2017-12-14
CA3031995A1 (en) 2018-02-22
EP3500593B1 (en) 2021-08-25
DK3500593T3 (da) 2021-11-01
DE102016115246C5 (de) 2018-12-20
CR20190095A (es) 2019-06-13
MX2019001769A (es) 2019-07-08
MX395287B (es) 2025-03-25
JP2021184729A (ja) 2021-12-09
PE20190477A1 (es) 2019-04-04
WO2018033291A1 (en) 2018-02-22
JP2019528061A (ja) 2019-10-10
JP6964351B2 (ja) 2021-11-10
MA45976B1 (fr) 2021-09-30
US10526407B2 (en) 2020-01-07

Similar Documents

Publication Publication Date Title
US10526407B2 (en) T cell receptors and immune therapy using the same
US11939376B2 (en) T cell receptors and immune therapy using the same
US10725044B2 (en) T cell receptors and immune therapy using the same
EP3551221B1 (en) Novel t cell receptors and immune therapy using the same
EP3645573B1 (en) Novel t cell receptors and immune therapy using the same
EP4219543A1 (en) Novel engineered t cell receptors and immune therapy using the same
EP3707159B1 (en) Novel engineered t cell receptors and immune therapy using the same
TWI790162B (zh) 新穎t細胞受器及使用其之免疫治療
HK40071461A (en) T cell receptors and immune therapy using the same
HK40010473B (en) T cell receptors and immune therapy using the same
HK40028715B (en) Novel engineered t cell receptors and immune therapy using the same
HK40028715A (en) Novel engineered t cell receptors and immune therapy using the same
HK40014640B (en) Novel t cell receptors and immune therapy using the same
HK40014640A (en) Novel t cell receptors and immune therapy using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired